Search Results - E. A. Kudryashov

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Propafenone in complex anti-recurrent therapy of persistent atrial fibrillation by V. V. Skibitsky, E. A. Kudryashov, A. V. Fendrikova, N. A. Spiropulos

    Published 2007-08-01

    Effectiveness and safety of Class IС antiarrhythmic agent, propafenone (Propanorm, PRO. MED. CS Praha a.s., Czech Republic), was studied inpatients with persistent atrial fibrillation (PAF) after sinus rhythm conversion, during long-term ant-recurrent treatment. The study included 30 men and women;...

    Full description

    Get full text
    Article
  2. 2

    GENDER SPECIFICS OF THE COMBINATION ANTIHYPERTENSION THERAPY EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION AND ISCHEMIC HEART DISEASE by V. V. Skibitsky, E. V. Gorodetskaya, A. V. Fendrikova, E. A. Kudryashov

    Published 2014-10-01

    Aim. To evaluate gender specifics of the efficacy of combination antihypertensive therapy by zofenopril and valsartan by QD or BID schedule in patients with arterial (AH) and stable coronary heart disease (CHD).Material and methods. Totally 98 men and 100 women were included with AH and CHD, who wer...

    Full description

    Get full text
    Article
  3. 3

    Propafenone efficacy in paroxysmal atrial fibrillation by V. V. Skibitsky, E. A. Kudryashov, N. A. Spiropulos, A. M. Kramskaya, Z. T. Sokaeva

    Published 2004-12-01

    Efficacy and safety of class IС antiarrhythmic agent, propafenone, was investigated in patients with paroxysmal atrial fibrillation (PAF), after single-dose load and during long-term preventive treatment. The study included 20 male and female patients (mean age 53,8+2,4 years). PAF was caused by cor...

    Full description

    Get full text
    Article
  4. 4

    Left ventricular function in patients with cardiorenal pathology and chronic renal failure by M. M. Dudar, A. V. Fendrikova, A. K. Arutyunov, E. A. Kudryashov, V. V. Skibitsky

    Published 2006-06-01

    Prognosis inpatients with pre-dialysis stages of chronic renal failure (CRF) is determined by various factors, including left ventricular hypertrophy (LVH) and coronary heart disease (CHD). At the same time, remodeling features and diastolic LV myocardial function in CRF patients are still understud...

    Full description

    Get full text
    Article
  5. 5

    Features and main problems of treating patients with high and very high cardiovascular risk with statins in real clinical practice (according to the data of the “PRIORITET” researc... by S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, N. A. Dmitrieva, T. A. Gomova, S. I. Drozdetsky, E. A. Kudryashov, O. V. Lerman, N. F. Puchinyan, V. V. Skibitsky

    Published 2018-12-01

    Aim. To determine the features and main problems of statin therapy, as well as assess the possibility of achieving the target level of lipid pattern in patients with high and very high cardiovascular risk (CVR) in real clinical practice.Material and methods. The design of the “PRIORITET” observation...

    Full description

    Get full text
    Article
  6. 6

    Adherence to Statins Therapy of High and Very High Cardiovascular Risk Patients in Real Clinical Practice: Diagnostics and Possible Ways to Solve the Problem (According to the PRIO... by S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, N. A. Dmitrieva, S. V. Blagodatskikh, O. V. Lerman, T. A. Gomova, S. I. Drozdetsky, V. V. Skibitskiy, E. A. Kudryashov, N. F. Puchinyan

    Published 2019-01-01

    Aim. To study adherence to treatment with generic statins prescribed to patients with high and very high cardiovascular risk in routine clinical practice, as well as the possible impact of educational training of doctors on compliance with clinical guidelines and changes in patient adherence to trea...

    Full description

    Get full text
    Article